bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
Authors: Beider Katia , Ribakovsky Elena , Abraham Michal , Wald Hanna , Weiss Lola , Rosenberg Evgenia , Galun Eithan , Avigdor Abraham , Eizenberg Orly , Peled Amnon , Nagler Arnon
Published: April 2023

Supplementary Figure 4 - PDF file 117K, Interaction of NHL cells with BMSCs
Supplementary Figure 3 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
Authors: Beider Katia , Ribakovsky Elena , Abraham Michal , Wald Hanna , Weiss Lola , Rosenberg Evgenia , Galun Eithan , Avigdor Abraham , Eizenberg Orly , Peled Amnon , Nagler Arnon
Published: April 2023

Supplementary Figure 3 - PDF file 100K, Apoptosis induced by BKT140 and Rituximab
Supplementary Table 1 from Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
Authors: Ardiani Andressa , Farsaci Benedetto , Rogers Connie J. , Protter Andy , Guo Zhimin , King Thomas H. , Apelian David , Hodge James W.
Published: April 2023

PDF file - 2461K, Supplemental Table 1: Cellular immune responses to multiple tumor antigens after combination therapy with MDV3100 and Twist-vaccine.
Supplementary Figure 1 from LAP+CD4+ T Cells Are Suppressors Accumulated in the Tumor Sites and Associated with the Progression of Colorectal Cancer
Authors: Mahalingam Jayashri , Lin Yung-Chang , Chiang Jy-Ming , Su Po-Jung , Fang Jian-He , Chu Yu-Yi , Huang Ching-Tai , Chiu Cheng-Tang , Lin Chun-Yen
Published: April 2023

PDF file, 146K, Figure S1: Expressions of Cytokines in CD4+LAP+, CD4+Foxp3- and CD8+ T cells. The dot blot showed the expression of IFN-γ, IL-17, IL-2 and IL-10 on LAP+CD4+ T cells, Foxp3-CD4+ T cells and total CD8+ T cells were analyzed by FACS Calibur.
Supplementary Figure 1 from Role of Hedgehog Signaling in Malignant Pleural Mesothelioma
Authors: Shi Yandong , Moura Ubiratan , Opitz Isabelle , Soltermann Alex , Rehrauer Hubert , Thies Svenja , Weder Walter , Stahel Rolf A. , Felley-Bosco Emanuela
Published: April 2023

PDF file, 96K, 1A. Expression of HH pathway components in non-tumoral pleural tissue and mesothelioma tumors. Quantitative real-time PCR analysis of SMO, GLI2, IHH, DHH gene expression in non-tumoral pleural tissue (NT) and tumor (T). 1B. Overall survival is inversely correlated with high GLI1 expression (delta Ct below the median) (p=0.042, low GLI1: median survival 22.9 months, 95% confidence interval 0.4- 45.4 months; high GLI1: median survival 17.0 months, 95% confidence interval 9.0- 25.1 months ).
Table S3 from Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer
Authors: Sun Nan , Chen Zhaoli , Tan Fengwei , Zhang Baihua , Yao Ran , Zhou Chengcheng , Li Jiagen , Gao Yibo , Liu Ziyuan , Tan Xiaogang , Zhou Fang , He Max Y.F , Shao Kang , Li Ning , Qiu Bin , Sun Jian , Yu Yue , Wang Suya , Zhao Yuda , Shi Xuejiao , He Jie
Published: April 2023

The diagnostic effect of IDH1 after stratification in smokers and non-smokers.
Figure S4 from Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model
Authors: Williams Emily L. , Dunn Stuart N. , James Sonya , Johnson Peter W. , Cragg Mark S. , Glennie Martin J. , Gray Juliet C.
Published: April 2023

Figure S4 - PDF file 53K, Figure S4. Splenocyte lysis was not enhanced by GWEPDDNPI-peptide pulsing. Thirty-five days after therapy, splenocytes from NXS2 inoculated mice received anti-CTLA-4/GWEPDDNPI-peptide were re-stimulated alongside splenocytes from naive mice with GWEPDDNPI-pulsed, irradiated splenocytes for 6 days. Target-cells were labeled with 51Cr and incubated with effectors at 50:1, 10:1 and 1:1 effector:target (E:T) ratio for 5 hr under tissue culture condition before determining the % lysis of target-cells. Target cell lysis was not enhanced when the cells were pulsed with a control or GWEPDDNPI peptide. Data represent examples of at least three experiments, where n = 3 mice/group. Error is expressed as SEM. * p < 0.05, n.s. not significant
Supplementary Methods from A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer
Authors: Socinski Mark A. , Goldman Jonathan , El-Hariry Iman , Koczywas Marianna , Vukovic Vojo , Horn Leora , Paschold Eugene , Salgia Ravi , West Howard , Sequist Lecia V. , Bonomi Philip , Brahmer Julie , Chen Lin-Chi , Sandler Alan , Belani Chandra P. , Webb Timothy , Harper Harry , Huberman Mark , Ramalingam Suresh , Wong Kwok-Kin , Teofilovici Florentina , Guo Wei , Shapiro Geoffrey I.
Published: April 2023

PDF file - 91K
Supplementary Table 4 from PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
Authors: Abiko Kaoru , Mandai Masaki , Hamanishi Junzo , Yoshioka Yumiko , Matsumura Noriomi , Baba Tsukasa , Yamaguchi Ken , Murakami Ryusuke , Yamamoto Ayaka , Kharma Budiman , Kosaka Kenzo , Konishi Ikuo
Published: April 2023

XLSX file - 63K, Table S4 shows FDR q value and FWER p value in the result of GSEA. Up-regulated genes in PD-L1 affected mouse CTLs and up-regulated genes in PD-1-signal-transmitted human CTLs show significant correlation, and so do the down-regulated genes.
Supplementary Table 3 from PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
Authors: Abiko Kaoru , Mandai Masaki , Hamanishi Junzo , Yoshioka Yumiko , Matsumura Noriomi , Baba Tsukasa , Yamaguchi Ken , Murakami Ryusuke , Yamamoto Ayaka , Kharma Budiman , Kosaka Kenzo , Konishi Ikuo
Published: April 2023

XLSX file - 136K, Table S3 shows probes significantly up-regulated and down-regulated in PD-L1-affected mouse CTLs. "-" in gene symbol means that the probe has no annotated gene.
Supplementary Table S1. Toxicities. from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Authors: Slingluff Craig L. , Petroni Gina R. , Molhoek Kerrington R. , Brautigan David L. , Chianese-Bullock Kimberly A. , Shada Amber L. , Smolkin Mark E. , Olson Walter C. , Gaucher Alison , Chase Cheryl Murphy , Grosh William W. , Weiss Geoffrey R. , Wagenseller Aubrey G. , Olszanski Anthony J. , Martin Lainie , Shea Sofia M. , Erdag Gulsun , Ram Prahlad , Gershenwald Jeffrey E. , Weber Michael J.
Published: April 2023

Detail of treatment-related toxicities.
Supplementary Figure 1 from PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
Authors: Abiko Kaoru , Mandai Masaki , Hamanishi Junzo , Yoshioka Yumiko , Matsumura Noriomi , Baba Tsukasa , Yamaguchi Ken , Murakami Ryusuke , Yamamoto Ayaka , Kharma Budiman , Kosaka Kenzo , Konishi Ikuo
Published: April 2023

PDF file - 153K, A. Overall survival of peritoneal cytology negative and positive patients in KOV-IH-65. B. Progression-free survival of peritoneal cytology negative and positive patients in KOV-IH-65. C. PD-L1-manipulated cell lines were generated from ID8 (left panel) and HM-1 (right panel). PD-L1 expression in the PD-L1-overexpressing cell line (thin line), the PD-L1-depleted cell line (thick line), and the control cell line (shaded). D. PD-L1 expression in HM1-control and HM1-Mirpdl1 after co-incubation with mouse ascites cells or mouse ascites CD8+ cells.
Supplementary Methods from A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Authors: Tang Hao , Xiao Guanghua , Behrens Carmen , Schiller Joan , Allen Jeffrey , Chow Chi-Wan , Suraokar Milind , Corvalan Alejandro , Mao Jianhua , White Michael A. , Wistuba Ignacio I. , Minna John D. , Xie Yang
Published: April 2023

PDF file - 33K
Supplementary Figure Legend from A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Authors: Tang Hao , Xiao Guanghua , Behrens Carmen , Schiller Joan , Allen Jeffrey , Chow Chi-Wan , Suraokar Milind , Corvalan Alejandro , Mao Jianhua , White Michael A. , Wistuba Ignacio I. , Minna John D. , Xie Yang
Published: April 2023

PDF file - 21K
Supplementary Figure 1 from A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Authors: Tang Hao , Xiao Guanghua , Behrens Carmen , Schiller Joan , Allen Jeffrey , Chow Chi-Wan , Suraokar Milind , Corvalan Alejandro , Mao Jianhua , White Michael A. , Wistuba Ignacio I. , Minna John D. , Xie Yang
Published: April 2023

PDF file - 521K, Different expression profiles of hub genes between the lung adenocarcinoma (ADC) group and lung squamous cell carcinoma (SCC) group.
Figure S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Authors: Kurzrock Razelle , Voorhees Peter M. , Casper Corey , Furman Richard R. , Fayad Luis , Lonial Sagar , Borghaei Hossein , Jagannath Sundar , Sokol Lubomir , Usmani Saad Z. , van de Velde Helgi , Qin Xiang , Puchalski Thomas A. , Hall Brett , Reddy Manjula , Qi Ming , van Rhee Frits
Published: April 2023

Figure S1 - PDF file 23K, Mean serum siltuximab concentration following the first dose of 12 mg/kg by disease type in patients evaluable for pharmacokinetics analysis in cohorts 3, 5, and 6. Abbreviations: CD, Castleman's disease; Inf, infusion; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma
Supplemental Figures Legend from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Authors: Van Looy Thomas , Wozniak Agnieszka , Floris Giuseppe , Sciot Raf , Li Haifu , Wellens Jasmien , Vanleeuw Ulla , Fletcher Jonathan A. , Manley Paul W. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

Supplemental Figures Legend
Data Supplement from T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Authors: Pinto Filipe , Pértega-Gomes Nelma , Pereira Márcia S. , Vizcaíno José R. , Monteiro Pedro , Henrique Rui M. , Baltazar Fátima , Andrade Raquel P. , Reis Rui M.
Published: April 2023

Supplementary Figure S1. Brachyury protein staining analysis in PCa tissues.
Data Supplement from T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Authors: Pinto Filipe , Pértega-Gomes Nelma , Pereira Márcia S. , Vizcaíno José R. , Monteiro Pedro , Henrique Rui M. , Baltazar Fátima , Andrade Raquel P. , Reis Rui M.
Published: April 2023

Supplementary Figure S2. The percentage of Brachyury-positive cases increases proportionally with Gleason score aggressiveness.
Supplementary Figure 8 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 30K, VEGF production by A375/H-2Db/gp100 melanoma cells
Data Supplement from Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Authors: Suryani Santi , Carol Hernan , Chonghaile Triona Ni , Frismantas Viktoras , Sarmah Chintanu , High Laura , Bornhauser Beat , Cowley Mark J. , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Tonna Elise , Jones Luke , Manesh Donya Moradi , Kurmasheva Raushan T. , Billups Catherine , Kaplan Warren , Letai Anthony , Bourquin Jean-Pierre , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Figures S2-S5. Responses of the remaining MLL-ALL xenografts not shown in Figure 2; S3. Responses of the remaining BCP-ALL xenografts not shown in Figure 2; S4. Responses of the remaining T-ALL xenografts not shown in Figure 2; S5. Correlation of xenograft in vivo responses to single agent ABT-263 with an induction-type combination regimen of vincristine, dexamethasone and L-asparaginase (VXL)
Data Supplement from Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Authors: Suryani Santi , Carol Hernan , Chonghaile Triona Ni , Frismantas Viktoras , Sarmah Chintanu , High Laura , Bornhauser Beat , Cowley Mark J. , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Tonna Elise , Jones Luke , Manesh Donya Moradi , Kurmasheva Raushan T. , Billups Catherine , Kaplan Warren , Letai Anthony , Bourquin Jean-Pierre , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Figures S10-S13. In vitro xenograft responses to ABT-263 by co-culture assay; S11. Formulae to determine assay sensitivity and specificity; S12. Live and dead cell analysis of each xenograft sample using 7-AAD staining and flow cytometry; S13. Comparison of ABT-263 responses for 5 xenograft samples in co-culture system versus single-cell suspension
Data Supplement from Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Authors: Suryani Santi , Carol Hernan , Chonghaile Triona Ni , Frismantas Viktoras , Sarmah Chintanu , High Laura , Bornhauser Beat , Cowley Mark J. , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Tonna Elise , Jones Luke , Manesh Donya Moradi , Kurmasheva Raushan T. , Billups Catherine , Kaplan Warren , Letai Anthony , Bourquin Jean-Pierre , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Figures S14-S15. In vivo efficacy of ABT-263 in combination with established drugs against ALL-2, ALL-19 and ALL-31; S15. MCL1 protein expression at different stages of spleen extraction
Supplementary Figure 1 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 31K, PLX4720 enhances MART-1-specific T-cell recognition of BRAF mutant melanomas
Supplementary Table 1 from Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Authors: Centenera Margaret M. , Gillis Joanna L. , Hanson Adrienne R. , Jindal Shalini , Taylor Renea A. , Risbridger Gail P. , Sutherland Peter D. , Scher Howard I. , Raj Ganesh V. , Knudsen Karen E. , Yeadon Trina , Tilley Wayne D. , Butler Lisa M.
Published: April 2023

PDF file, 70KB, Primary antibodies used for immunoblotting and immunohistochemistry.
Supplementary Figure 2 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
Authors: Aarntzen Erik H. J. G. , Schreibelt Gerty , Bol Kalijn , Lesterhuis W. Joost , Croockewit Alexandra J. , de Wilt Johannes H. W. , van Rossum Michelle M. , Blokx Willeke A. M. , Jacobs Joannes F. M. , Duiveman-de Boer Tjitske , Schuurhuis Danita H. , Mus Roel , Thielemans Kris , de Vries I. Jolanda M. , Figdor Carl G. , Punt Cornelis J. A. , Adema Gosse J.
Published: April 2023

PDF file, 1359K, Vaccine characteristics of first cycle of all patients. (A) Expression of HLA-ABC, HLA-DR/DP, HLA-DQ, CD80, CD86, CD83, and CCR7 was analyzed by flow cytometry. (B) Tumor antigen expression by DCs 2-4 hrs after electroporation with mRNA encoding gp100 and tyrosinase. Data are shown as percentage of positive DCs used for the first vaccination. The graphs represent mean � SD of all patients.
Supplementary Figure 2 from Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Authors: Centenera Margaret M. , Gillis Joanna L. , Hanson Adrienne R. , Jindal Shalini , Taylor Renea A. , Risbridger Gail P. , Sutherland Peter D. , Scher Howard I. , Raj Ganesh V. , Knudsen Karen E. , Yeadon Trina , Tilley Wayne D. , Butler Lisa M.
Published: April 2023

PDF file, 92KB, (A) PC-3 and (B) LNCaP prostate cancer cells were cultured in medium containing vehicle or 40nM 17-AAG for 96 hours, stained with propidium iodide and analysed by flow cytometry. Cell cycle distibution was determined using FlowJo software. Histograms are representative of 2 independent experiments containing triplicate wells.
Table S1-S3 from Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Authors: Merino Diana M. , Shlien Adam , Villani Anita , Pienkowska Malgorzata , Mack Stephen , Ramaswamy Vijay , Shih David , Tatevossian Ruth , Novokmet Ana , Choufani Sanaa , Dvir Rina , Ben-Arush Myran , Harris Brent T. , Hwang Eugene I. , Lulla Rishi , Pfister Stefan M. , Achatz Maria Isabel , Jabado Nada , Finlay Jonathan L. , Weksberg Rosanna , Bouffet Eric , Hawkins Cynthia , Taylor Michael D. , Tabori Uri , Ellison David W. , Gilbertson Richard J. , Malkin David
Published: April 2023

Table S1-S3. S1Choroid plexus tumor chromosomal instability reported in literature S2-Characterization of patient and sample cohort used in analysis S3 Frequency of TP53 mutations in CPTs and characterization of mutation types. Abbreviations: CPC: choroid plexus carcinoma, CPP: choroid plexus papilloma, aCPP: atypical choroid plexus papilloma, SH3: SRC Homology 3 Domain
Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Authors: Frantzi Maria , van Kessel Kim E. , Zwarthoff Ellen C. , Marquez Mirari , Rava Marta , Malats Núria , Merseburger Axel S. , Katafigiotis Ioannis , Stravodimos Konstantinos , Mullen William , Zoidakis Jerome , Makridakis Manousos , Pejchinovski Martin , Critselis Elena , Lichtinghagen Ralph , Brand Korbinian , Dakna Mohammed , Roubelakis Maria G. , Theodorescu Dan , Vlahou Antonia , Mischak Harald , Anagnou Nicholas P.
Published: April 2023

Supplementary Table S7. Logistic regression analysis to investigate the potential confounding effect of previous supplementary treatment in the classification score of the 106 peptide biomarker panel.
Supplementary Figures S1 to S14 from Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation
Authors: Palanichamy Kamalakannan , Thirumoorthy Krishnan , Kanji Suman , Gordon Nicolaus , Singh Rajbir , Jacob John R. , Sebastian Nikhil , Litzenberg Kevin T. , Patel Disha , Bassett Emily , Ramasubramanian Brinda , Lautenschlaeger Tim , Fischer Steven M. , Ray-Chaudhury Abhik , Chakravarti Arnab
Published: April 2023

Supporting Figures Figure S1. Extracellular and intracellular metabolites of commercially available and patient derived GBM cells and NHAs Figure S2. Total and extracted ion chromatograms of intracellular metabolites Figure S3. Total and extracted ion chromatograms of extracellular metabolites Figure S4. Targeted analysis MS/MS product ion spectrum of methionine Figure S5. Targeted analysis MS/MS product ion spectrum of tryptophan Figure S6. Targeted analysis MS/MS product ion spectrum of kynurenine Figure S7. Targeted analysis MS/MS product ion spectrum of MTA Figure S8. Total ion chromatogram and multiple reaction monitoring of different concentrations of methionine Figure S9. Total ion chromatogram and multiple reaction monitoring of different concentrations of kynurenine Figure S10. Key metabolites in methionine pathway Figure S11. Calibration Curve and Multiple Reaction Monitoring of SAM and SAH Figure S12. Key metabolites in tryptophan pathway Figure S13. Insilico analysis - Connecting metabolome and proteome in GBM cells Figure S14. Densitometric quantification of the chemiluminescence signals
Table S1 from Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Authors: Schneider Marc A. , Granzow Martin , Warth Arne , Schnabel Philipp A. , Thomas Michael , Herth Felix J.F. , Dienemann Hendrik , Muley Thomas , Meister Michael
Published: April 2023

Table S1. Most regulated genes after PAEP knockdown in Affymetrix gene expression analyses.
Figure S4 from Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Authors: Schneider Marc A. , Granzow Martin , Warth Arne , Schnabel Philipp A. , Thomas Michael , Herth Felix J.F. , Dienemann Hendrik , Muley Thomas , Meister Michael
Published: April 2023

Figure S4. Experiments performed in melanoma cell line MeWo.
Figure S3 from Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Authors: Schneider Marc A. , Granzow Martin , Warth Arne , Schnabel Philipp A. , Thomas Michael , Herth Felix J.F. , Dienemann Hendrik , Muley Thomas , Meister Michael
Published: April 2023

Figure S3. Additional information of ELISA experiments.
Figure S2 from Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Authors: Schneider Marc A. , Granzow Martin , Warth Arne , Schnabel Philipp A. , Thomas Michael , Herth Felix J.F. , Dienemann Hendrik , Muley Thomas , Meister Michael
Published: April 2023

Figure S2. Antibody controls and glycodelin expression of patient 2106.
Supplemental Figure 2 from Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
Authors: Chacon Jessica Ann , Sarnaik Amod A. , Chen Jie Qing , Creasy Caitlin , Kale Charuta , Robinson John , Weber Jeffrey , Hwu Patrick , Pilon-Thomas Shari , Radvanyi Laszlo
Published: April 2023

Supplemental Figure 2. Testing of different concentrations of agonist anti-4-1BB antibody added to melanoma tumor fragment cultures.
Supplemental Methods from Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer
Authors: Bottsford-Miller Justin , Choi Hyun-Jin , Dalton Heather J. , Stone Rebecca L. , Cho Min Soon , Haemmerle Monika , Nick Alpa M. , Pradeep Sunila , Zand Behrouz , Previs Rebecca A. , Pecot Chad V. , Crane Erin King , Hu Wei , Lutgendorf Susan K. , Afshar-Kharghan Vahid , Sood Anil K.
Published: April 2023

Supplemental Methods. The supplementary methods section describes in greater detail how platelets were isolated from whole mouse blood, how the in vitro apoptosis assay was performed, how cleaved caspace 3 immunohistochemistry was performed, how platelet transfusion was performed, and how aspirinization of platelets prior to transfusion was performed. The supplementary data includes a table detailing the demographic characteristics of the patients included in the clinical component of the work as well as the details of platelet change over the course of primary therapy.
Supplementary Figure S4 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Authors: Pokorny Jenny L. , Calligaris David , Gupta Shiv K. , Iyekegbe Dennis O. , Mueller Dustin , Bakken Katrina K. , Carlson Brett L. , Schroeder Mark A. , Evans Debra L. , Lou Zhenkun , Decker Paul A. , Eckel-Passow Jeanette E. , Pucci Vincenzo , Ma Bennett , Shumway Stuart D. , Elmquist William F. , Agar Nathalie Y.R. , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S4. Evaluation of MK-1775 therapy in GBM12 orthotopic and flank xenograft models.
Supplementary Figure S2 from The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Authors: Wen Chi-Pang , Zhang Fanmao , Liang Dong , Wen Christopher , Gu Jian , Skinner Heath , Chow Wong-Ho , Ye Yuanqing , Pu Xia , Hildebrandt Michelle A.T. , Huang Maosheng , Chen Chien-Hua , Hsiung Chao Agnes , Tsai Min Kuang , Tsao Chwen Keng , Lippman Scott M. , Wu Xifeng
Published: April 2023

Supplementary Figure S2. Adjusted HRs of lung cancer incidence and mortality stratified by tertiles of serum total bilirubin level and smoking intensity
Data Supplement from SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Authors: Deckert Jutta , Wetzel Marie-Cécile , Bartle Laura M. , Skaletskaya Anna , Goldmacher Victor S. , Vallée François , Zhou-Liu Qing , Ferrari Paul , Pouzieux Stéphanie , Lahoute Charlotte , Dumontet Charles , Plesa Adriana , Chiron Marielle , Lejeune Pascale , Chittenden Thomas , Park Peter U. , Blanc Véronique
Published: April 2023

Supplementary Figure S3. Simultaneous binding of SAR650984 and anti-CD38 antibody HB7
Supplemental Figure S2 from On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Authors: Gehrke Iris , Bouchard Eric D.J. , Beiggi Sara , Poeppl Armando G. , Johnston James B. , Gibson Spencer B. , Banerji Versha
Published: April 2023

Figure S2: CLL samples were separated into treatment-naïve and relapsed subgroups with failure of at least one line of treatment qualifying for being considered relapsed (Tab. S1). Fisher´s exact test and univariable logistic regression analysis revealed a statistically significant increased LD50 for FK866 in relapsed samples (Tab. S2). When multivariable regression model was constructed to control for CD38, this significance disappeared (data not shown).
Supplemental Figure Legend from On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Authors: Gehrke Iris , Bouchard Eric D.J. , Beiggi Sara , Poeppl Armando G. , Johnston James B. , Gibson Spencer B. , Banerji Versha
Published: April 2023

Supplemental Figure Legend from On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Supplementary Methods, Tables 1 - 4, Figures 1 - 10 from Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Authors: Califano Joseph A. , Khan Zubair , Noonan Kimberly A. , Rudraraju Lakshmi , Zhang Zhe , Wang Hao , Goodman Steven , Gourin Christine G. , Ha Patrick K. , Fakhry Carole , Saunders John , Levine Marshall , Tang Mei , Neuner Geoffrey , Richmon Jeremy D. , Blanco Ray , Agrawal Nishant , Koch Wayne M. , Marur Shanthi , Weed Donald T. , Serafini Paolo , Borrello Ivan
Published: April 2023

Supplementary Table 1: Change in immune response by treatment group and HPV status for analyzed cohort n=32. Supplementary Table 2: Change in immune response by treatment group and HPV status for intent to treat cohort. Supplementary Table 3: Baseline Characteristics of the Intent to treat population. Supplementary Table 4: Pre and post changes in immune response outcomes between treatment arms (Intent to Treat cohort n=40). Supplementary Table 5 Correlations among changes in immune response outcomes in analyzed cohort. Supplementary Figure 1: Additional graphs of immune parameters. Supplementary Figure 2: Change in immune response by treatment group and HPV status. Supplementary Figure 3: Graphic relationship between immune response measures. Supplementary Figure 4 and 5: Gating strategy for the MDSC phenotype in this study defined as CD14+ or CD15+/CD33+/HLA-DRint/low/IL-4Ra+ as well as co-expression of CD14+/CD15+/ CD33+/HLA-DRint/low/IL-4Ra+. Supplementary Figure 6: Outliers from DTH assay are graphed on a larger scale for visualization. Supplementary Figure 7: Study Schema. Supplementary Figure 8: Correlation of BMI with change in primary immune response outcomes. Supplementary Figure 9: Correlations of BSA with change in primary immune response outcomes. Supplementary Figure 10: Correlations of BSA with change in primary immune response outcomes.
Supplementary Figure 1 from Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials
Authors: Rafii Saeed , Roda Desamparados , Geuna Elena , Jimenez Begona , Rihawi Karim , Capelan Marta , Yap Timothy A. , Molife L. Rhoda , Kaye Stanley B. , de Bono Johann S. , Banerji Udai
Published: April 2023

Supplementary Figure 1. Occurence of infection during treatment with single agent PI3K-AKT-mTOR inhibitors
Supplemental Table and Figure Legends from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Authors: Cooper Todd M. , Cassar Jeannette , Eckroth Elena , Malvar Jemily , Sposto Richard , Gaynon Paul , Chang Bill H. , Gore Lia , August Keith , Pollard Jessica A. , DuBois Steven G. , Silverman Lewis B. , Oesterheld Javier , Gammon Guy , Magoon Daniel , Annesley Colleen , Brown Patrick A.
Published: April 2023

Supplemental Figure 1 and Figure 2 Legends Supplemental Tables 1-5 Legends
Supplementary Figure Legends from Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers
Authors: Lombardi Anne J. , Hoskins Elizabeth E. , Foglesong Grant D. , Wikenheiser-Brokamp Kathryn A. , Wiesmüller Lisa , Hanenberg Helmut , Andreassen Paul R. , Jacobs Allison J. , Olson Susan B. , Keeble Winifred W. , Hays Laura E. , Wells Susanne I.
Published: April 2023

Legends for supplementary figures and table
Figure S2 from Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers
Authors: Lombardi Anne J. , Hoskins Elizabeth E. , Foglesong Grant D. , Wikenheiser-Brokamp Kathryn A. , Wiesmüller Lisa , Hanenberg Helmut , Andreassen Paul R. , Jacobs Allison J. , Olson Susan B. , Keeble Winifred W. , Hays Laura E. , Wells Susanne I.
Published: April 2023

Figure S2. Crosslinker and chemotherapy sensitivity of human FA-deficient and -proficient HNSCC lines
Data Supplement from An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer
Authors: Noguchi Satoshi , Saito Akira , Horie Masafumi , Mikami Yu , Suzuki Hiroshi I. , Morishita Yasuyuki , Ohshima Mitsuhiro , Abiko Yoshimitsu , Mattsson Johanna Sofia Margareta , König Helena , Lohr Miriam , Edlund Karolina , Botling Johan , Micke Patrick , Nagase Takahide
Published: April 2023

Supplementary Figure S3. Involvement of TAZ in tumorigenesis.
Supplementary Table 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
Authors: Wheeler Heather E. , Gamazon Eric R. , Wing Claudia , Njiaju Uchenna O. , Njoku Chidiamara , Baldwin Robert Michael , Owzar Kouros , Jiang Chen , Watson Dorothy , Shterev Ivo , Kubo Michiaki , Zembutsu Hitoshi , Winer Eric P. , Hudis Clifford A. , Shulman Lawrence N. , Nakamura Yusuke , Ratain Mark J. , Kroetz Deanna L. , Cox Nancy J. , Dolan Mary Eileen
Published: April 2023

PDF file - 68K, Positional information and effect sizes of the 24 patient/LCL overlap SNPs.
Supplementary Appendices from Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic
Authors: Tang Chad , Hess Kenneth , Jardim Denis Leonardo F. , Gagliato Debora De Melo , Tsimberidou Apostolia M. , Falchook Gerald , Fu Siqing , Janku Filip , Naing Aung , Piha-Paul Sarina , Subbiah Vivek , Wheler Jennifer , Zinner Ralph G. , Kurzrock Razelle , Ellis Lee M. , Meric-Berstam Funda , Hong David S.
Published: April 2023

Supplementary Appendices. Supplemental Appendix 1: List of Trials by NCT numbers Supplementary Appendix 2: Synergy and antagonism interaction examples
Supplementary Table 3 from Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer
Authors: Ciarloni Laura , Ehrensberger Sahar Hosseinian , Imaizumi Natsuko , Monnier-Benoit Sylvain , Nichita Cristina , Myung Seung-Jae , Kim Joo Sung , Song Si Young , Kim Tae Il , van der Weg Boudewijn , Meier Rémy , Borovicka Jan , Beglinger Christoph , Vallet Cédric , Maerten Philippe , Rüegg Curzio , Dorta Gian
Published: April 2023

Positive rate of the MGMC and MGMC-P algorithms for non-colorectal cancers. This table provides the positive rate of the MGMC and MGMC-P algorithms for non-colorectal cancers
Supplementary Table 2 from Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer
Authors: Ciarloni Laura , Ehrensberger Sahar Hosseinian , Imaizumi Natsuko , Monnier-Benoit Sylvain , Nichita Cristina , Myung Seung-Jae , Kim Joo Sung , Song Si Young , Kim Tae Il , van der Weg Boudewijn , Meier Rémy , Borovicka Jan , Beglinger Christoph , Vallet Cédric , Maerten Philippe , Rüegg Curzio , Dorta Gian
Published: April 2023

Gene expression analysis of the 29 biomarkers according to age and sex in the 3 main study groups. Two sided t-test was used to test genes differentially expressed between subjects younger or older than 65 years or between males and females. Statistical significance threshold was set at 0.05.
Supplementary Table 1 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Authors: Sarker Debashis , Ang Joo Ern , Baird Richard , Kristeleit Rebecca , Shah Krunal , Moreno Victor , Clarke Paul A. , Raynaud Florence I. , Levy Gallia , Ware Joseph A. , Mazina Kathryn , Lin Ray , Wu Jenny , Fredrickson Jill , Spoerke Jill M. , Lackner Mark R. , Yan Yibing , Friedman Lori S. , Kaye Stan B. , Derynck Mika K. , Workman Paul , de Bono Johann S.
Published: April 2023

Supplementary Table 1. Additional pharmacokinetic parameters of pictilisib
Supplementary Figure 2 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Authors: Sarker Debashis , Ang Joo Ern , Baird Richard , Kristeleit Rebecca , Shah Krunal , Moreno Victor , Clarke Paul A. , Raynaud Florence I. , Levy Gallia , Ware Joseph A. , Mazina Kathryn , Lin Ray , Wu Jenny , Fredrickson Jill , Spoerke Jill M. , Lackner Mark R. , Yan Yibing , Friedman Lori S. , Kaye Stan B. , Derynck Mika K. , Workman Paul , de Bono Johann S.
Published: April 2023

Supplementary Figure 2. Waterfall plot of changes in18F-FDG-PET SUVmax grouped according to pictilisib AUC as assessed by an independent review facility.
Supplementary Figure 1 from Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
Authors: Julien Sylvia , Merino-Trigo Ana , Lacroix Ludovic , Pocard Marc , Goéré Diane , Mariani Pascale , Landron Sophie , Bigot Ludovic , Nemati Fariba , Dartigues Peggy , Weiswald Louis-Bastien , Lantuas Denis , Morgand Loïc , Pham Emmanuel , Gonin Patrick , Dangles-Marie Virginie , Job Bastien , Dessen Philippe , Bruno Alain , Pierré Alain , De Thé Hugues , Soliman Hany , Nunes Manoel , Lardier Guillaume , Calvet Loreley , Demers Brigitte , Prévost Grégoire , Vrignaud Patricia , Roman-Roman Sergio , Duchamp Olivier , Berthet Cyril
Published: April 2023

PDF file, 156K, Histopathological characterization of the tumor samples.
Data Supplement from Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History
Authors: Karlsson Anna , Ringnér Markus , Lauss Martin , Botling Johan , Micke Patrick , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Table S1. Clinicopathological characteristics of individual adenocarcinoma cohorts in the combined 1398-sample genomic cohort.
Data Supplement from Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Authors: Zhang Zhe , Wang Jiping , Ji Dongmei , Wang Chenchen , Liu Rujiao , Wu Zheng , Liu Lian , Zhu Dan , Chang Jinjia , Geng Ruixuan , Xiong Lei , Fang Qiangyi , Li Jin
Published: April 2023

Supplementary Figure 3. TKIs' Effects on the Corresponding Receptors Were Confirmed by Western Blot Analysis
Supplementary Figure S4 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
Authors: Rivoltini Licia , Chiodoni Claudia , Squarcina Paola , Tortoreto Monica , Villa Antonello , Vergani Barbara , Bürdek Maja , Botti Laura , Arioli Ivano , Cova Agata , Mauri Giorgio , Vergani Elisabetta , Bianchi Beatrice , Della Mina Pamela , Cantone Laura , Bollati Valentina , Zaffaroni Nadia , Gianni Alessandro Massimo , Colombo Mario Paolo , Huber Veronica
Published: April 2023

Supplementary Figure S4. Pharmacokinetics and biodistribution of i.v.-injected TRAIL exosomes. Detection and quantification of TRAIL exosomes in plasma by Near-Infrared imaging (A) and TRAIL ELISA (B) after 1, 5, 60 and 180 minutes post-injection. Imaging and quantification of Near-Infrared-labeled TRAIL exosomes in organs (spleen, kidneys, liver and lungs) 1, 3 and 24 h after injection.
Data Supplement from GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion
Authors: Zhang Hong , Hou Wei , Wang Hua-Li , Liu Hai-Jing , Jia Xin-Ying , Zheng Xing-Zheng , Zou Yong-Xin , Li Xin , Hou Lin , McNutt Michael A. , Zhang Bo
Published: April 2023

Supplementary Figure S3. The transcriptional activity of NAT10 promoter by luciferase assay.
Supplemental Tables 1 & 2 from An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2
Authors: Cardnell Robert J.G. , Behrens Carmen , Diao Lixia , Fan YouHong , Tang Ximing , Tong Pan , Minna John D. , Mills Gordon B. , Heymach John V. , Wistuba Ignacio I. , Wang Jing , Byers Lauren A.
Published: April 2023

Supplemental Tables 1 & 2. Table 1: Significant protein changes between TTF1-low and -high tumors in PROSPECT. Table 2: Significant protein changes between TTF1-low and -high tumors in TCGA.
Data Supplement from Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis
Authors: Liu Zhaojun , Zhang Jun , Gao Yanhong , Pei Lirong , Zhou Jing , Gu Liankun , Zhang Lianhai , Zhu Budong , Hattori Naoko , Ji Jiafu , Yuasa Yasuhito , Kim Wooho , Ushijima Toshikazu , Shi Huidong , Deng Dajun
Published: April 2023

Supplementary Figure S1. Workflow for characterization of GC metastasis biomarkers.
Supplemental Figure 1 from An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2
Authors: Cardnell Robert J.G. , Behrens Carmen , Diao Lixia , Fan YouHong , Tang Ximing , Tong Pan , Minna John D. , Mills Gordon B. , Heymach John V. , Wistuba Ignacio I. , Wang Jing , Byers Lauren A.
Published: April 2023

Supplemental Figure 1. Comparison of TTF1 by RPPA and mRNA in TCGA shiws a string positive correlation.
Supplementary Figure 5 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers
Authors: Hu Hanguang , Zhang Hang , Ge Weiting , Liu Xiyong , Loera Sofia , Chu Peiguo , Chen Huarong , Peng Jiaping , Zhou Lun , Yu Shujing , Yuan Ying , Zhang Suzhan , Lai Lily , Yen Yun , Zheng Shu
Published: April 2023

PDF file, 89K, Standard of cytoplasm staining of SPARCL1.
supplemental legend from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Authors: Sborov Douglas W. , Nuovo Gerard J. , Stiff Andrew , Mace Thomas , Lesinski Gregory B. , Benson Don M. , Efebera Yvonne A. , Rosko Ashley E. , Pichiorri Flavia , Grever Michael R. , Hofmeister Craig C.
Published: April 2023

supplemental legend
Supplementary Figure 1 from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
Authors: Kennedy-Nasser Alana A. , Ku Stephanie , Castillo-Caro Paul , Hazrat Yasmin , Wu Meng-Fen , Liu Hao , Melenhorst Jos , Barrett A. John , Ito Sawa , Foster Aaron , Savoldo Barbara , Yvon Eric , Carrum George , Ramos Carlos A. , Krance Robert A. , Leung Kathryn , Heslop Helen E. , Brenner Malcolm K. , Bollard Catherine M.
Published: April 2023

PDF file - 26KB, General Immune reconstitution. Immune reconstitution was evaluated in individual patients after transplant. Phenotyping was performed on PBMC to evaluate for the presence of NK cells (A), CD8+ T-cells (B), CD4+ T cells (C), B cells (D) and CD56+/CD3+ NK-like T-cells (E).
Supplemental Table 1 from Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Authors: Merchant Melinda S. , Bernstein Donna , Amoako Martha , Baird Kristin , Fleisher Thomas A. , Morre Michel , Steinberg Seth M. , Sabatino Marianna , Stroncek Dave F. , Venkatasan Aradhana M. , Wood Bradford J. , Wright Matthew , Zhang Hua , Mackall Crystal L.
Published: April 2023

Grade 3, 4 Toxicities Possibly Related and Grade 2 Toxicities Likely Related to Regimen
Supplementary Figure S2 from Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses
Authors: Lamothe Betty , Wierda William G. , Keating Michael J. , Gandhi Varsha
Published: April 2023

Supplementary Figure S2. Depletion of Noxa by shRNA approach was achieved only with 2 shRNA and conferred protective effect against carfilzomib cytotoxic response.
Supplementary Figure Legends from To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Authors: Shiwarski Daniel J. , Shao Chunbo , Bill Anke , Kim Jean , Xiao Dong , Bertrand Carol A. , Seethala Raja S. , Sano Daisuke , Myers Jeffery N. , Ha Patrick , Grandis Jennifer , Gaither L. Alex , Puthenveedu Manojkumar A. , Duvvuri Umamaheswar
Published: April 2023

PDF file - 87K
Supplementary Figure 6 from β-1,4-Galactosyltransferase III Enhances Invasive Phenotypes Via β1-Integrin and Predicts Poor Prognosis in Neuroblastoma
Authors: Chang Hsiu-Hao , Chen Chia-Hua , Chou Chih-Hsing , Liao Yung-Feng , Huang Miao-Juei , Chen Ya-Hsin , Wang Wei-Jen , Huang John , Hung Ji-Shiang , Ho Wan-Ling , Jeng Yung-Ming , Che Mei-Ieng , Lee Hsinyu , Lu Meng-Yao , Yang Yung-Li , Jou Shiann-Tarng , Lin Dong-Tsamn , Lin Kai-Hsin , Hsu Wen-Ming , Huang Min-Chuan
Published: April 2023

PDF file - 48K, Effects of B4GALT3 on cell migration toward β1-integrin substrates, fibronectin and laminin
Supplementary Figure 2 from β-1,4-Galactosyltransferase III Enhances Invasive Phenotypes Via β1-Integrin and Predicts Poor Prognosis in Neuroblastoma
Authors: Chang Hsiu-Hao , Chen Chia-Hua , Chou Chih-Hsing , Liao Yung-Feng , Huang Miao-Juei , Chen Ya-Hsin , Wang Wei-Jen , Huang John , Hung Ji-Shiang , Ho Wan-Ling , Jeng Yung-Ming , Che Mei-Ieng , Lee Hsinyu , Lu Meng-Yao , Yang Yung-Li , Jou Shiann-Tarng , Lin Dong-Tsamn , Lin Kai-Hsin , Hsu Wen-Ming , Huang Min-Chuan
Published: April 2023

PDF file - 62K, Transient overexpression of B4GALT3 in SK-N-AS cells and knockdown of B4GALT3 in SK-N-BE cells
Supplementary Figure 2 from To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Authors: Shiwarski Daniel J. , Shao Chunbo , Bill Anke , Kim Jean , Xiao Dong , Bertrand Carol A. , Seethala Raja S. , Sano Daisuke , Myers Jeffery N. , Ha Patrick , Grandis Jennifer , Gaither L. Alex , Puthenveedu Manojkumar A. , Duvvuri Umamaheswar
Published: April 2023

PDF file - 202K, Knockdown of TMEM16A in T24 cancer cells decreases motility and migration.
Supplementary Methods and Tables 1 - 2 from The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Authors: Carol Hernan , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

PDF file - 171K, Includes summary statistics and analysis methods, Table S1 and Table S2
Supplementary Figure from Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4–CHOP–DR5 Axis in Human Esophageal Cancer Cells
Authors: Chen Ping , Hu Tao , Liang Yupei , Li Pei , Chen Xiaoyu , Zhang Jingyang , Ma Yangcheng , Hao Qianyun , Wang Jinwu , Zhang Ping , Zhang Yanmei , Zhao Hu , Yang Shengli , Yu Jinha , Jeong Lak Shin , Qi Hui , Yang Meng , Hoffman Robert M. , Dong Ziming , Jia Lijun
Published: April 2023

Supplementary Figure S1. Expression of the global neddylation protein, NEDD8-activating enzyme E1 and NEDD8-conjugating enzyme E2 in ESCC tissues Supplementary Figure S2. Expression of death-receptor family and Bcl-2 family members Supplementary Figure S3. MLN4924 acted on DR5-mediated apoptosis independently of Trail. Kyse450 and EC1 cells were transfected (48 hours) with control or Trail siRNA, treated with 0.6 μM MLN4924 (48 hours). Supplementary Figure S4. MLN4924 inhibited the polyubiquitination modification of ATF4. A, MLN4924 increased the mRNA level of CHOP while little effect on ATF4 mRNA level. Supplementary Figure S5. A, Knockdown efficiency of ATF4. Kyse450 and EC1 cells were transfected with control or ATF4 siRNA for 24 hours and then treated with 0.6 μM MLN4924 for 48 hours Supplementary Figure S6. Genetic inactivation of neddylation pathway via NAE1/UBA3 siRNA silencing recapitulates MLN4924-induced cellular responses in ESCC cells. Supplementary Figure S7. No body weight loss occurred during treatment. Body weight of the animals was measured and recorded during the treatment period.
Supplementary Figure 1 from CADM1 Expression and Stepwise Downregulation of CD7 Are Closely Associated with Clonal Expansion of HTLV-I–Infected Cells in Adult T-cell Leukemia/Lymphoma
Authors: Kobayashi Seiichiro , Nakano Kazumi , Watanabe Eri , Ishigaki Tomohiro , Ohno Nobuhiro , Yuji Koichiro , Oyaizu Naoki , Asanuma Satomi , Yamagishi Makoto , Yamochi Tadanori , Watanabe Nobukazu , Tojo Arinobu , Watanabe Toshiki , Uchimaru Kaoru
Published: April 2023

PDF file - 51KB, Representative flow cytometric analysis of a patient with smoldering-type ATL (patient no. 12).
Supplementary Figure 3 from Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model
Authors: Bai Ren-Yuan , Staedtke Verena , Wanjiku Teresia , Rudek Michelle A. , Joshi Avadhut , Gallia Gary L. , Riggins Gregory J.
Published: April 2023

Supplementary Figure 3. Treatment of GL261 glioma-bearing mice with MBZ-NH2 or MBZ-OH
Supplementary Figure 2 from Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model
Authors: Bai Ren-Yuan , Staedtke Verena , Wanjiku Teresia , Rudek Michelle A. , Joshi Avadhut , Gallia Gary L. , Riggins Gregory J.
Published: April 2023

Supplementary Figure 2. Test of benzimidazoles in GL261 glioma mouse model.
Supplementary Table 1 from Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas
Authors: Eruslanov Evgeniy , Stoffs Taryn , Kim Wan-Ju , Daurkin Irina , Gilbert Scott M. , Su Li-Ming , Vieweg Johannes , Daaka Yehia , Kusmartsev Sergei
Published: April 2023

PDF file - 54K, Summary data for patients
Supplementary Methods from Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas
Authors: Eruslanov Evgeniy , Stoffs Taryn , Kim Wan-Ju , Daurkin Irina , Gilbert Scott M. , Su Li-Ming , Vieweg Johannes , Daaka Yehia , Kusmartsev Sergei
Published: April 2023

PDF file - 111K